Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Nuvalent, Inc.

$123.96

0 (0%)

Last traded Jul 14, 2026. This price is not current.

C 52Pipeline Score Overvalued Pharma · Clinical
Market Cap
8.07 B
EPS
-6.06
P/E Ratio
-
Value Trade
133.89 M
-1.35 %
Week
-5.24 %
1 Month
-1.17 %
3 Month
-4.52 %
6 Month
464.2 %
5 Year
464.2 %
All Time
Cash Data

  • Cash Position

    -

  • Monthly Burn

    -

  • Runway

    -

Overview
Volume
3.07 M
52 Week Range
70.25 - 113.02
% held by Insiders
32.95 %
% held by Institutions
72.61 %
Enterprise Value
6.78 B
Total Shares
67.26 M
Short %
1.53 %
Float Shares
46.81 M
Company Description
HQ: ONE BROADWAY, 14TH FLOOR, CAMB...
Employees:228
https://www.nuvalent.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
PDUFA Date example
zidesamtinib Adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who received at least 1 prior ROS1 TKI
BreakthroughOrphan
PDUFA
—

Subscribe to access the data.

Small Molecules
Oncology
zidesamtinib Adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who received at least 1 prior ROS1 TKI
BreakthroughOrphan
PDUFA
—

Subscribe to access the data.

Small Molecules
Oncology
zidesamtinib Adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who received at least 1 prior ROS1 TKI
BreakthroughOrphan
PDUFA
—

Subscribe to access the data.

Small Molecules
Oncology
Unlock Upcoming Catalyst data

Catalyst Timeline

Dated clinical, regulatory & corporate events for Nuvalent, Inc.

320Total events
9Upcoming
55Tier-1 (high impact)
2021 – 2028Coverage

Upcoming catalysts 2

TBD
T1PDUFA Date
Subscribe to view catalyst details
ZidesamtinibFiled
TBD
T1PDUFA Date
Subscribe to view catalyst details
NeladalkibFiled

Event history 2

TBD
◆NDA SubmissionZidesamtinibFiledRegulatory Filing
Subscribe to view catalyst details
TBD
▲AcquiredCorporate
Subscribe to view catalyst details
Unlock the full Catalyst Timeline
Past FDA Catalysts & PDUFA Decisions
Date Drug Catalyst Stage Outcome Reaction Event Move % Best Trade %
2025-12-31
neladalkib (ALK-selective inhibitor)
Top-line Data
Phase 2
—
–
–
–
2025-12-31
neladalkib (ALK-selective inhibitor)
Top-line Data
Phase 2
—
–
–
–
2025-12-31
neladalkib (ALK-selective inhibitor)
Top-line Data
Phase 2
—
–
–
–
Unlock 4 more historical catalysts
Drug Pipeline Intelligence
C52
Pipeline Score
$1.8B
Pipeline Value
Overvalued
Valuation Signal
3
Drugs Scored
0.2x
rNPV / MCap
Top 83%
Small Cap
(rank 160 of 933)
Percentile Rank
Nuvalent, Inc. carries a moderate pipeline score (52/100), with $2.8B risk-adjusted pipeline value, led by Neladalkib in Non-small Cell Lung Cancer (Phase 3).
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
Neladalkib
Small molecule		Non-small Cell Lung CancerPhase 3NCT0676510987% $2.3B RECRUITING 450 VERY_FAST C (59) Dec 1, 2029MODERATE_RISKLOW
Jul 21, 2026
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
neladalkib
BreakthroughOrphan
advanced ALK-positive NSCLC
Phase 1/2
2026-05-21

encouraging activity in TKI pre-treated patients

Nuvalent Highlights Upcoming Data Presentations for Neladalkib and Zidesamtinib at the 2026 American Society of Clinical Oncology Annual Meeting Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven...

Read More
neladalkib
BreakthroughOrphan
advanced ALK-positive NSCLC
Phase 1/2
2026-05-21

encouraging activity in TKI pre-treated patients

Nuvalent Highlights Upcoming Data Presentations for Neladalkib and Zidesamtinib at the 2026 American Society of Clinical Oncology Annual Meeting Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven...

Read More
neladalkib
BreakthroughOrphan
advanced ALK-positive NSCLC
Phase 1/2
2026-05-21

encouraging activity in TKI pre-treated patients

Nuvalent Highlights Upcoming Data Presentations for Neladalkib and Zidesamtinib at the 2026 American Society of Clinical Oncology Annual Meeting Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven...

Read More
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in NUVL
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
NUVL Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
Competitive Position
How NUVL ranks across every disease it competes in
Competitive Position is a premium feature
See how NUVL ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial